RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 17 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 17

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  2. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  3. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  4. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  5. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  6. Study siteNanchang People's HospitalNanchangHospital page
  7. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  8. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  9. Study siteNorthern Jiangsu People's Hospital江苏省苏北人民医院YangzhouHospital page
  10. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  11. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  12. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  13. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  14. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  15. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  16. Study siteXi'an International Medical Center Hospital西安国际医学中心医院Xi'anHospital page
  17. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06757634, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced HR+/HER2- breast cancer

    Inclusion criterion 1

  3. Negative pregnancy test for females of childbearing potential. Female subjects who are not surgically sterile must use a medically effective contraceptive method from screening until 2 years after the last dose of study treatment.

    Inclusion criterion 3

    Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor or any other selective estrogen receptor degrader (SERD), except fulvestrant, used in (neo)adjuvant setting.

    Exclusion criterion 2

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

    Inclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06757634, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of metastatic or locally advanced HR+/HER2- breast cancer
  • Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue for the duration of the study.
  • Negative pregnancy test for females of childbearing potential. Female subjects who are not surgically sterile must use a medically effective contraceptive method from screening until 2 years after the last dose of study treatment.
  • Progression of disease during or within 12 months of completing (neo)adjuvant endocrine therapy (ET) or progression of disease after 12 months of completing (neo)adjuvant ET.
  • Adequate archival, fresh tumor tissue, or liquid biopsy for the analysis of PIK3CA mutational status.
  • Permitted prior therapies:
  • (neo)adjuvant fulvestrant only if the treatment duration < 6 months
  • (neo)adjuvant chemotherapy
  • (neo)adjuvant CDK4/6 inhibitor, unless PD was on or within 6 months of discontinuation of CDK4/6i

i. Study 1: if disease progression was on or within event occurred >6 months of discontinuation after completion of CDK4/6 inhibitor portion of treatment.

ii. Study 2: if disease progression event occurred >12 months after completion of CDK4/6 inhibitor portion of treatment.

  • Subject has radiologically measurable disease according to RECIST v1.1, per local assessment. Patients with nonmeasurable bone-only disease are not eligible. Patients with bone-only disease that has lytic or mixed lytic/blastic lesions and at least one measurable soft tissue component per RECIST v1.1 may be eligible.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Life expectancy of at least >6 months.
  • Adequate bone marrow, hepatic, renal and coagulation function.

Exclusion Criteria:

  • Concurrent malignancies other than adequately treated non-melanoma skin cancer. Previous malignancies in remission but curatively treated with no evidence of disease progression and judged by local Investigator to be at low risk of impacting health or survival while on study.
  • Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor or any other selective estrogen receptor degrader (SERD), except fulvestrant, used in (neo)adjuvant setting.
  • Prior treatment with systemic anticancer therapy for ABC
  • Subjects with type 1 diabetes, or uncontrolled type 2 diabetes requiring daily insulin therapy.
  • Known and untreated, or active, brain or leptomeningeal metastases
  • History of clinically significant cardiovascular abnormalities
  • Known, clinically significant ophthalmic conditions
  • History of drug-induced symptomatic interstitial lung disease (pneumonitis) or hepatitis

Quoted from ClinicalTrials.gov, NCT06757634, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06757634, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06757634